<DOC>
	<DOCNO>NCT02477800</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy monthly dos aducanumab slow cognitive functional impairment measure change Clinical Dementia Rating-Sum Boxes ( CDR-SB ) score compare placebo participant early AD . Secondary objective assess effect monthly dos aducanumab compare placebo clinical progression measure Mini-Mental State Examination ( MMSE ) , AD Assessment Scale-Cognitive Subscale ( 13 item ) [ ADAS-Cog 13 ] , AD Cooperative Study-Activities Daily Living Inventory ( Mild Cognitive Impairment version ) [ ADCS-ADL-MCI ] .</brief_summary>
	<brief_title>221AD301 Phase 3 Study Aducanumab ( BIIB037 ) Early Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Key Must meet follow clinical criterion MCI due AD mild AD must : A Clinical Dementia Rating ( CDR ) Global Score 0.5 . Objective evidence cognitive impairment screen An MMSE score 24 30 ( inclusive ) Must positive amyloid Positron Emission Tomography ( PET ) scan Must consent apolipoprotein E ( ApoE ) genotyping If use drug treat symptom related AD , dose must stable least 8 week prior screen visit 1 Must reliable informant caregiver Key Any medical neurological condition ( Alzheimer 's Disease ) might contribute cause subject 's cognitive impairment Have stroke Transient Ischemic Attack ( TIA ) unexplained loss consciousness past 1 year Clinically significant psychiatric illness past 6 month History unstable angina , myocardial infarction , advance chronic heart failure , clinically significant conduction abnormality within 1 year prior Screening Indication impair renal liver function Have human immunodeficiency virus ( HIV ) infection Have significant systematic illness infection past 30 day Relevant brain hemorrhage , bleed disorder cerebrovascular abnormality Any contraindication brain magnetic resonance imaging ( MRI ) PET scan Alcohol substance abuse past 1 year Taking blood thinner ( except aspirin prophylactic dose less ) NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>BIIB037</keyword>
	<keyword>Aducanumab</keyword>
</DOC>